Details of the Drug Pharmacogenomic Perturbation Atlas

General Information of Drug (ID: DMMLXA9)

Drug Name
Sotagliflozin Drug Info
Synonyms
1018899-04-1; LX-4211; LX4211; UNII-6B4ZBS263Y; 6B4ZBS263Y; AK170751; (2s,3r,4r,5s,6r)-2-(4-chloro-3-(4-ethoxybenzyl)phenyl)-6-(methylthio)tetrahydro-2h-pyran-3,4,5-triol; b-L-Xylopyranoside, methyl 5-C-[4-chloro-3-[(4-ethoxyphenyl)methyl]phenyl]-1-thio-, (5S)-;b-L-Xylopyranoside, methyl 5-C-[4-chloro-3-[(4-ethoxyphenyl)methyl]phenyl]-1-thio-, (5S)-; Sotagliflozin [USAN:INN]; beta-l-Xylopyranoside, methyl 5-C-(4-chloro-3-((4-ethoxyphenyl)methyl)phenyl)-1-thio-, (5S)-; LX 4211; Tube103; LP 802034
Cross-matching ID
PubChem CID
24831714
ChEBI ID
CHEMBL3039507
CAS Number
CAS 1018899-04-1
TTD Drug ID
D0U7IL
VARIDT Drug ID
DR01138

Consensus Signature of Drug Pharmacogenomic Perturbation (DPP)
Term Name NES FDR q-val Tag % Leading Edge Genes
Mucin type O-glycan biosynthesis 1.83 1.13e-1 20/36 (55.56%) GALNT7;GALNT1;GALNT11;...
Non-homologous end-joining 1.77 9.55e-2 11/13 (84.62%) DCLRE1C;DNTT;XRCC5;...
Staphylococcus aureus infection 1.76 6.66e-2 72/95 (75.79%) KRT16;KRT17;KRT13;...
Complement and coagulation cascades 1.74 7.17e-2 76/85 (89.41%) SERPINA1;F3;CLU;...
Protein export 1.61 2.29e-1 17/23 (73.91%) SRPRB;SRPRA;SEC61G;...
SNARE interactions in vesicular transport 1.57 2.78e-1 19/33 (57.58%) SNAP29;STX7;STX16;...
African trypanosomiasis 1.56 2.52e-1 32/37 (86.49%) HBB;TNF;PLCB1;...
Dilated cardiomyopathy 1.56 2.26e-1 86/96 (89.58%) TNF;ITGA6;TPM4;...
Aldosterone-regulated sodium reabsorption 1.55 2.16e-1 34/37 (91.89%) SFN;IRS1;MAPK1;...
Type II diabetes mellitus 1.55 1.99e-1 42/46 (91.3%) TNF;HK2;IRS1;...
Hypertrophic cardiomyopathy 1.55 1.81e-1 81/90 (90%) TNF;ITGA6;TPM4;...
Other types of O-glycan biosynthesis 1.50 2.48e-1 29/47 (61.7%) COLGALT2;GALNT7;GALNT1;...
Fc gamma R-mediated phagocytosis 1.46 2.87e-1 79/97 (81.44%) ARPC5;PLPP1;MARCKSL1;...
Selenocompound metabolism 1.42 3.82e-1 11/17 (64.71%) SEPHS1;KYAT3;SEPHS2
p53 signaling pathway 1.41 3.60e-1 63/73 (86.3%) SERPINB5;SFN;IGFBP3;...
Renin-angiotensin system 1.40 3.77e-1 20/23 (86.96%) MME;KLK2;AGT;...
Autophagy 1.34 5.19e-1 113/169 (66.86%) IRS1;MAPK1;PIK3C3;...
Arrhythmogenic right ventricular cardiomyopathy 1.33 5.30e-1 70/77 (90.91%) LEF1;ITGA6;DSC2;...
Glutamatergic synapse 1.32 5.60e-1 97/114 (85.09%) GRIA2;PLCB1;GNG5;...
Cardiac muscle contraction 1.31 5.53e-1 64/87 (73.56%) TPM4;TPM2;ACTC1;...
Carbohydrate digestion and absorption 1.30 5.97e-1 37/47 (78.72%) SLC2A5;HK2;PLCB1;...
Leishmaniasis 1.29 5.90e-1 67/77 (87.01%) TNF;STAT1;MARCKSL1;...
Progesterone-mediated oocyte maturation 1.28 6.24e-1 75/100 (75%) CDC25B;MAPK1;CDC25A;...
AGE-RAGE signaling pathway in diabetic complications 1.26 6.44e-1 97/100 (97%) F3;TNF;PLCB1;...
Basal cell carcinoma 1.26 6.36e-1 41/63 (65.08%) LEF1;FZD7;PTCH1;...
Estrogen signaling pathway 1.24 6.59e-1 119/137 (86.86%) KRT16;KRT17;KRT13;...
Inositol phosphate metabolism 1.19 6.53e-1 66/73 (90.41%) PLCB1;PI4KA;PIK3C3;...
Circadian entrainment 1.10 6.53e-1 85/97 (87.63%) GRIA2;PLCB1;GNG5;...
Cholinergic synapse 1.10 6.43e-1 99/113 (87.61%) PLCB1;GNG5;MAPK1;...
IL-17 signaling pathway 1.08 6.58e-1 84/94 (89.36%) TNF;CCL20;CXCL5;...
Glycolysis / Gluconeogenesis -1.28 5.57e-1 56/67 (83.58%) HK1;ENO1;PFKM;...
Tyrosine metabolism -1.29 5.21e-1 30/36 (83.33%) ALDH3B1;AOC3;MIF;...
Relaxin signaling pathway -1.30 5.31e-1 114/129 (88.37%) ADCY2;SHC3;GNA15;...
Parkinson disease -1.30 5.49e-1 176/249 (70.68%) SEM1;BCL2L1;ATP5F1B;...
Rheumatoid arthritis -1.30 5.56e-1 78/93 (83.87%) LTB;ATP6V1A;MMP3;...
Sphingolipid metabolism -1.31 5.23e-1 32/49 (65.31%) PSAP;SMPD3;CERS6;...
VEGF signaling pathway -1.32 5.16e-1 50/59 (84.75%) PIK3CD;PLA2G4A;KDR;...
Various types of N-glycan biosynthesis -1.35 4.42e-1 26/39 (66.67%) DAD1;MGAT4A;HEXB;...
JAK-STAT signaling pathway -1.36 4.21e-1 146/162 (90.12%) CNTFR;EPO;IL24;...
Propanoate metabolism -1.37 4.18e-1 30/34 (88.24%) HADHA;BCKDHA;ACOX3;...
Tryptophan metabolism -1.37 4.10e-1 35/42 (83.33%) ACAT1;CAT;TDO2;...
Synthesis and degradation of ketone bodies -1.37 4.30e-1 9/10 (90%) HMGCL;HMGCS1;ACAT1;...
Rap1 signaling pathway -1.38 4.33e-1 184/210 (87.62%) CALML4;ITGA2B;KRIT1;...
Biosynthesis of unsaturated fatty acids -1.39 4.27e-1 21/27 (77.78%) HACD1;ACOX3;ELOVL4;...
ErbB signaling pathway -1.42 3.69e-1 79/85 (92.94%) PRKCA;PIK3R2;AKT1;...
Primary bile acid biosynthesis -1.42 3.82e-1 15/17 (88.24%) CYP39A1;ACOX2;CYP7A1;...
Sulfur relay system -1.42 4.06e-1 5/8 (62.5%) MOCS3;NFS1;MPST;...
Chronic myeloid leukemia -1.44 3.90e-1 72/76 (94.74%) GADD45A;PIK3R2;AKT1;...
Valine, leucine and isoleucine degradation -1.44 4.23e-1 42/48 (87.5%) HADHA;ACAD8;BCKDHA;...
Pyruvate metabolism -1.45 4.20e-1 41/47 (87.23%) ACACB;PKM;MDH2;...
D-Glutamine and D-glutamate metabolism -1.46 4.18e-1 5/5 (100%) GLS2;GLUD1;GLS
Galactose metabolism -1.50 3.61e-1 26/31 (83.87%) AKR1B10;HK1;PFKM;...
Bile secretion -1.55 2.55e-1 68/90 (75.56%) ABCC2;ATP1B3;ADCY2;...
Caffeine metabolism -1.59 1.92e-1 5/6 (83.33%) NAT1;NAT2
Glycerolipid metabolism -1.60 1.99e-1 44/61 (72.13%) GLA;ALDH1B1;AGPAT2;...
Terpenoid backbone biosynthesis -1.60 2.39e-1 18/22 (81.82%) PMVK;MVK;HMGCS1;...
Fatty acid elongation -1.61 2.87e-1 19/27 (70.37%) HSD17B12;PPT2;HADHA;...
Aminoacyl-tRNA biosynthesis -1.64 3.10e-1 15/66 (22.73%) FARSA;DARS2;WARS2;...
Fatty acid degradation -1.77 1.43e-1 40/43 (93.02%) HADHA;ACSBG1;HADH;...
Steroid biosynthesis -1.84 1.38e-1 19/20 (95%) SOAT1;SOAT2;TM7SF2;...
×

Pharmacogenomic Perturbation Across Diseases and Tissues

Bone
Ewing sarcoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
SK-ES-1 CVCL_0627 Homo sapiens 1.11uM - 10uM 24H
Brain
Glioma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
GI-1 CVCL_1230 Homo sapiens 1.11uM - 10uM 24H
Breast
Breast adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
MDA-MB-468 CVCL_0419 Homo sapiens 1.11uM - 10uM 24H
Breast ductal carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
T-47D CVCL_0553 Homo sapiens 1.11uM - 10uM 24H
Colon
Colorectal adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
SNU-407 CVCL_5004 Homo sapiens 1.11uM - 10uM 24H
Endometrium
Endometrial adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HEC-108 CVCL_2926 Homo sapiens 1.11uM - 10uM 24H
HEC-1-A CVCL_0293 Homo sapiens 1.11uM - 10uM 24H
HEC-251 CVCL_2928 Homo sapiens 1.11uM - 10uM 24H
HEC-265 CVCL_2929 Homo sapiens 1.11uM - 10uM 24H
Hematopoietic system
Normal
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
CJM CVCL_U797 Homo sapiens 1.11uM - 10uM 24H
Liver
Hepatocellular carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
JHH-5 CVCL_1320 Homo sapiens 1.11uM - 10uM 24H
Lung
Lung adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
NCI-H1573 CVCL_1483 Homo sapiens 1.11uM - 10uM 24H
NCI-H838 CVCL_1594 Homo sapiens 1.11uM - 10uM 24H
Lung squamous cell carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
BEN CVCL_1081 Homo sapiens 1.11uM - 10uM 24H
HCC95 CVCL_1276 Homo sapiens 1.11uM - 10uM 24H
Non-small cell lung carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
NCI-H2110 CVCL_1529 Homo sapiens 1.11uM - 10uM 24H
Muscle
Rhabdomyosarcoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A-204 CVCL_0134 Homo sapiens 1.11uM - 10uM 24H
Ovary
Ovarian clear cell carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
OVTOKO CVCL_3114 Homo sapiens 1.11uM - 10uM 24H
Prostate
Prostate carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
22Rv1 CVCL_1045 Homo sapiens 1.11uM - 10uM 24H
Skin
Melanoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
IGR-37 CVCL_1303 Homo sapiens 1.11uM - 10uM 24H
Mel-HO CVCL_1402 Homo sapiens 1.11uM - 10uM 24H
SH-4 CVCL_1692 Homo sapiens 1.11uM - 10uM 24H
Urinary bladder
Bladder carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
BC-3C CVCL_1079 Homo sapiens 1.11uM - 10uM 24H
Bladder transitional cell carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
CAL-29 CVCL_1109 Homo sapiens 1.11uM - 10uM 24H